Summary of Peppermint
Primary Information, Benefits, Effects, and Important Facts
Peppermint (Mentha piperita) is a plant which is a hybrid from watermint and spearmint, used initially for culinary and food manufacturing purposes but has also been used for its supposed medicinal benefits. Peppermint has an oil component which appears to be its medicinal component, and this oil has a very large content of menthol which is seen as its bioactive ingredient. This menthol is nontoxic at the recommended dose, but is the same menthol also found in some cigarette products.
The main medicinal role of peppermint is due to its muscle relaxing properties in the stomach and intestinal tract, and internal usage of peppermint appears to be able to speed up the early phase of digestion in the stomach while reducing colonic motility. It is known as a carminative agent (thought to relief flatulence), and it has a fair bit of evidence to supports its usage in reducing abdominal pain in persons with irritable bowel syndrome (IBS). It doesn't seem to influence other symptoms of IBS too much, but the reduction of abdominal pain is quite notable.
Other possible benefits of peppermint oil include fast headache relief (which involves applying a topical solution of 10% peppermint oil to the scalp at the onset of a tension headache) and possibly a reduction in nausea when used as aromatherapy. It is safe with the recommended dosages, but overconsumption of peppermint oil supplements does have a toxic level which is feasible to reach intentionally.
Things To Know & Note
Also Known As
Menthol, Mentha piperita, Mentha balsamea
Do Not Confuse With
Spearmint or Watermint (the plants from which peppermint is a hybrid)
Goes Well With
Topical absorption (may enhance absorption of other nutrients topically, as evidenced with aminophylline)
Caution NoticeExamine.com Medical Disclaimer
Has been noted to inhibit the conversion of nicotine into continine, which is thought to be due to inhibition of the CYP2D6 enzyme. While minor in potency, it does appear to be relevant to peppermint ingestion (study in question used tea)
Menthol can inhibit the CYP3A4 enzyme in humans with a fairly respectable potency, slightly less than grapefruit juice, and thus may be contraindicted when using select pharmaceuticals
How to Take Peppermint
Recommended dosage, active amounts, other details
Oral supplementation of peppermint oil for the purpose of gastrointestinal health and motility involves consuming anywhere between 450-750mg of the oil daily in 2-3 divided doses, and this is around 0.1-0.2mL of the oil itself per dosage. The exact optimal dosage of peppermint is not known, and the numbers reflect a menthol content somewhere between 33-50%.
Usage of peppermint for the treatment of headaches involves having a solution of 10% peppermint oil and applying a relatively thin layer to the front of your head upon the start of a headache, with another application after 15 minutes and 30 minutes (for three applications in total).
Usage of peppermint for aromatherapy does not follow any particular dosing, and similar to other forms of aromatherapy it should be used as either an oil or in a distiller until a pleasant aroma permeates the vicinity.
Any form of peppermint oil should be effective although for persons who experience heartburn (acid reflux) and wish to supplement with peppermint oil for their intestines, then an enteric coated capsule would be useful (since the muscle relaxing effects may affect the esophagous if the capsule breaks prematurely).
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects peppermint has on your body, and how strong these effects are.
|Grade||Level of Evidence [show legend]|
|Robust research conducted with repeated double-blind clinical trials|
|Multiple studies where at least two are double-blind and placebo controlled|
|Single double-blind study or multiple cohort studies|
|Uncontrolled or observational studies only|
Level of Evidence
? The amount of high quality evidence. The more evidence, the more we can trust the results.
Magnitude of effect
? The direction and size of the supplement's impact on each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
Consistency of research results
? Scientific research does not always agree. HIGH or VERY HIGH means that most of the scientific research agrees.
|Symptoms of Irritable Bowel Syndrome||Notable||Very High See all 8 studies|
|Nausea||Minor||High See all 5 studies|
|Treatment of Headaches||Notable||Very High See 2 studies|
|Colonic Tension||Minor||- See study|
|Flatulence||Minor||- See study|
|Irritability||Minor||- See study|
|Nipple Cracks||Minor||Very High See 2 studies|
|Pain||Minor||- See study|
|Rate of Gastric Emptying||Minor||- See study|
|Subjective Well-Being||Minor||Very High See all 3 studies|
|Treatment of Diffuse Esophageal Spasms||Notable||- See study|
|Attention||Minor||Moderate See 2 studies|
|Calmness||-||- See study|
|Memory||-||- See study|
|Processing Accuracy||-||- See study|
|Processing Speed||-||- See study|
|Sedation||-||- See study|
|Working Memory||-||- See study|
Studies Excluded from Consideration
Scientific Research on Peppermint
Click on any below to expand the corresponding section. Click on to collapse it.
Peppermint is a common spice that is a cross between two plants, watermint (Mentha aquatica) and spearmint (Mentha spicata) and is sometimes also referred to by the name of Mentha piperita or balsamea; the mentha genera refers to all mint plants in general, and they all belong to the Lamiaceae family. The herb is a traditional medicine for mostly gastrointestinal disorders, and has a GRAS status.
Peppermint is a hybrid plant, and it appears to have some medicial usage for gastrointestinal complications as well as being a general flavoring agent and spice
The essential oil fragment of peppermint oil (commonly called the 'peppermint oil') contains:
Neomenthol (trace to 4.6%)
(+)-pulegone (0.8-24.9%, highest in very young leaves and progessively declines)
Myrcene (trace to 0.7%)
α-terpineol (trace to 0.4%)
For the most part, the composition of peppermint oil is menthol. Very young leaves (not commonly used in supplementation) are a good source of limonene and pulegone, but these decline over the process of the leafs aging process and the oil accumulates around a third to half of its weight as menthol
Adding the scent and taste of peppermint to bitter tasting capsules (in this study, Famotidine) is able to mask the bitterness when orally ingested, and words in an additive manner with physical methods (coating a capsule to prevent the bitter molecules from touching sensors on the tongue).
May be useful in masking bitter tones
'Colpermin' is a pharmaceutical brand name for peppermint oil, in which one capsule contains 0.1mL of peppermint oil concentrated to 187mg of bioactives and around 60mg menthol per 0.1mL. Colpermin is a gel capsule with an enteric coating, and is unlikely to influence the esophageus or stomach as it disintegrates in the pH of the intestines
Mintec is also a delayed release formulation of peppermint oil with a somewhat comparable menthol content (110+/-5mg per 0.2mL or 55mg per 0.1mL) although mintec has a slightly faster release rate than does Colpermin.
Colpermin and Mintec are two brand names that both are enteric coated capsules with a delay release, designed specifically for the treatment of intestinal complications (since enteric capsules are degraded in the intestines and not stomach) and bypassing anything in the stomach or esophagus
Menthol-β-D-glucuronide is a prodrug variant of menthol. It is a glucuronide conjugate, and it is stable in the stomach and small intestine while degraded in the cecum and colon; this is thought to avoid any muscle relaxing properties in the esophagous or stomach while retaining the therapeutic effects on IBS and the colon.
Menthol-β-D-glucuronide is a variant of menthol that aims for the same purpose as enteric coated capsules, but it itself is not an enteric coating
Menthol appears to be metabolized predominately to menthol glucuronide in humans, with urinary menthol glucuronide reaching 65–68% of all absorbed menthol. Other minor metabolites include hydroxyl menthol glucuronide, dihydroxyl menthol glucuronide, and menthol sulfoconjugate and some metabolites such as aldehyde-hydroxyl menthol glucuronide or dialdehyde menthol glucuronide were barely detectable.
Menthol has a fairly wide variation in serum concentration and the time required to reach peak levels, and seems to be mostly metabolized by phase II conjugation (glucuronidation)
Topical application of aminophylline in a base of peppermint oil appears to have greater absorption relative to aminophylline alone (28% increased peak absorption), which was significantly greater than rosemary and ylang oils yet lesser than jojoba and ethanol.
Peppermint also appears to be recommended for headaches via topical application and a solution containing 10% peppermint oil and 90% ethanol has been shown to be bioactive in humans; while the aroma of peppermint was not ruled out in these studies, it is plausible that it can be topically absorbed.
Usage of peppermint oil as a base may enhance the absorption of other molecules slightly (less than ethanol as a reference) and it itself may be topically absorbed
Menthol appears to inhibit calcium channels with an IC50 in the range of 7.7-28.1µg/mL (intestinal cells), 17.2-26.6µg/mL (retinal cells), and 10.1-68.5µg/mL (cardiac cells) and is about two-fold more potent than peppermint oil itself (IC50 on retinal cells being 20.3-41.7µg/mL). It seems to influence intestinal cells more than cardiac and neuronal cells, and it is competitive with the pharmaceutical calcium channel blocker nitrendipine (when either menthol or peppermint oil is at 78µg/mL).
Menthol appears to be a calcium channel antagonist at the same binding site as nitrendipine
Menthol has been confirmed to inhibit coumarin 7-hydroxylation (CYP2D6 mediated) with an IC50 of 70.49μM (the (-)-menthol isomer) or 37.77μM (the (+)-menthol isomer) which is thought to underlie the increased ratio of nicotine to cotinine seen with coingestion of peppermint tea with nicotine, as nicotine is converted to cotinine by two enzymes (one of which is CYP2D6).
Peppermint also appears to inhibit CYP3A4 in a reversible manner, which was thought to be due to the menthol content; peppermint oil had a Ki of 35.9+/-3.3µg/mL and menthol a Ki of 87.0+/-7.0nM/mL. This was confirmed to increase the AUC of felodipine by 140%, which underperformed relative to grapefruit juice as a reference (173%).
Peppermint oil, due to the menthol component, appears to inhibit both the CYP2D6 enzyme and the CYP3A4 enzyme. This suggests a possibility for drug-drug interactions
Peppermint oil is commonly used in aromatherapy as a stimulating/arousing scent, which may be related to the 1,8-cineole content (thought to be the stimulating component in rosemary) which is present at 3.5-14% of the essential oil.
In an (unblinded) study using either peppermint or ylang-ylang (Cananga odorata) aromatherapy versus control, usage of a steam distiller to spread the aroma five minutes prior to cognitive testing found that peppermint failed to be associated with improved memory or recall and no significant alterations in cognition (speed, accuracy, and quality of memories or mood) although elsewhere during a sustained visual attention task (40m) task peppermint aroma (rated as pleasant to smell) has been noted to improve performance relative to no aroma. One trial has investigated the influence of peppermint aroma (20µL) on vigilence, and noted that it was improved relative to control early on in testing but not later on (whereas linalyl acetate, a component of lavender, was effective later).
There does appear to be some interactions with peppermint and attention, although it is not clear exactly how this interaction works. Beyond that, it is not sure if the influence on attention is due to the menthol component itself or due to the perception of a pleasurable scent (a relatively large confound in aromatherapy research)
A pilot study on aromatherapy assigning persons to either an aroma mixture (5:4:2:1 ratio of peppermint, basil, jojoba, and helichrysum) or placebo (rose water) noted that the intervention group had a significantly greater reduction in symptoms of mental fatigue and exhaustion (as assessed by a 0-10 rating scale), although the magnitude was small (0.2 point reduction).
No convincing evidence for an anti-fatigue effect of peppermint, as the only human study is confounded with other herbs and has a very small effect size
Beyond the traditional recommendations for peppermint oil against digestive disorders and its use as a carminative, it has also been recommended for reducing nausea (mostly secondary to its relaxing effect on stomach tissue). Peppermint (as well as various other aromatics) have been noted to be useful during labor, with half of women (n=8,058) rating aromatherapy as helpful and it being associated with less pain medication usage. Specifically for nausea, there were more women reporting peppermint oil as helpful (44-54%) than not helpful (11-17%).
Peppermint (as a spirit; peppermint in an aromatic ethyl alcohol base used as aromatherapy) is able to reduce post-operative nausea relative to control and placebo in women who underwent C-sections when aromatherapy is administered when women started to feel nauseous. The efficacy in this trial was relatively large, causing 55% of the subjects to experience no nausea within 5 minutes of inhalation and reducing the 55% of women who reported that they were 'about to vomit' down to 5-9% within 2-5 minutes.
A small placebo controlled pilot study in women who underwent major gynaecological surgery with peppermint essence (no menthol content) as placebo, the aroma of peppermint oil was associated with some slight reductions in nausea. A later double blind study in persons with postoperative nausea using the inhalation of peppermint oil noted that the benefits observed (reductions on a 100mm VAS scale from 60.6 down to 28) was not significantly different than placebo. This study did use a controlled breathing technique which could have explained the observed reductions in nausea, but it remains a possiblity that the peppermint that was lightly infused into the nurses masks (to blind the treatment to participants) could have influenced all groups.
Peppermint as aromatherapy is traditionally recommended for nausea, and while most preliminary research came back very positive the two double blind trials are opposite of each other (the more statistically robust one potentially having complications with the methods, and the one showing promise being much less robust). More evidence is needed
Peppermint appears to be traditionally recommended as a remedy for headaches when topically applied to the head.
10% peppermint oil preparation (90% ethanol) was effective in reducing tension headaches within 15 minutes when applied to the head at the onset of headaches and again at both 15 and 30 minutes afterwards; its potency was comparable to 1,000mg of the reference drug acetominophen with both treatments exceeding placebo. This same method of application has been used elsewhere in tension headaches (with or without 5% eucalyptus oil) with peppermint oil being confirmed to reduce temporal muscle activity by 28.8% (assesed by EMG) and improved mood state (irritability) relative to placebo.
It is thought that peppermint may also be beneficial for migraines since one of the measurements (Contingent negative variation or CNV) is known to be significantly increased in migraines without aura and it has been noted to be reduced by 35.3% with topical application of peppermint oil.
In tension headaches, peppermint as a topical application appears to be able to reduce muscular tension and improve symptoms associated with headaches. It is thought that this may be useful for migraines, and is effective within 15 minutes of topical application
Peppermint oil has been noted to inhibit the short circuit current (SCC) associated with glucose uptake at a concentration of 1-5mg/mL by around 58-59% (no concentration dependence noted, but 0.1-0.5mg/mL was ineffective) without any influence on basal SCC. This was though to be related to sodium channel inhibiting properties (since sodium dependent processes such as glycine or glucose absorption were also inhibited), and peppermint oil was able to inhibit glucose uptake in vitro by 45-65%.
It is plausible that peppermint can inhibit glucose uptake, but this has not yet been tested for biological relevance
Peppermint has been noted to influence up to 10.7% of muscle activity via aromatherapy, although the degree of change (stimulation of sedation) was not reliably predicted.
Aromatherapy of peppermint appears to influence muscle contractility, although how it influences it is not certain
The muscle relaxing properties of peppermint oil appear to apply to the throat and esophagus, insofar that peppermint oil is one of the first therapies to recommend in persons with esophageal spasms (after nitrates and calcium channel blockers).
In persons with diffuse esophageal spasm (a relatively rare esophageal disorder associated that may cause chest pain and dysphagia), supplementation of peppermint oil at 5 drops (in a 10mL solution) is able to abolish esophageal spasms in all patients tested in a pilot study.
Peppermint oil has shown antispasmolytic activity in a few medical instances, such as barium meal examination and during esophagogastroduodenoscopy where 20mL of a solution containing 1.6% peppermint oil performed equally to the other two therapies (20mg hyoscine butyl bromie and 1mg glucagon injections).
The muscle relaxing properties of peppermint oil appear to occur in the esophagous, and conditions associated with abnormal contractility or spasms are effectively treated with very low doses of peppermint oil
Gastroesophageal reflux disease (GERD; also known as heartburn and occurring when acidic stomach contents reflux into the esophagus) is known to interact with a few herbal remedies of which include peppermint which is thought to be related to the ability of peppermint to relax cells of the gastrointestinal path (IC50 between 15.2-25.9µg/mL). This muscle relaxing property of peppermint oil is associated with menthol's calcium channel inhibiting properties and it is thought that it may benefit symptoms of GERD by accelerating the passing of food in the stomach as demonstrated in otherwise healthy men given a 200mL test solution where Tlag and the β contant were reduced (T1/2 not); it was concluded that the early phase of gastric emptying was increased. Furthermore, peppermint oil has failed to alter gastric pH inherently although it also failed to increase the efficacy of lafutidine (H2 receptor antagonist) in reducing gastric pH.
Conversely, it has been hypothesized that the muscle relaxing effects of peppermint may influence the lower esophageal sphincter (LES) and exacerbate acid reflux. This has not been noted in persons with diffuse esophageal spasms given peppermint oil although some cases of using peppermint oil have reported heartburn to a level greater than placebo.
The muscle relaxing properties of peppermint can increase the speed of food passing through the stomach, and that is thought to reduce symptoms of GERD. However, supplementation may also reduce lower esopageal pressure and exacerbate symptoms of GERD. Overall there are mixed effects as to whether heartburn is treated or exacerbated with peppermint oil supplemention, and it may be advisable for those with GERD to use enteric coated capsules to avoid this issue
Peppermint oil has been confirmed to, as a intragastric spray during gastrointestinal endoscopy, cause relaxation of peristalsis in the stomach and could fully inhibit it in 35.6-37.5% of patients, with higher rates of complete suppression in those with heliobacter pylori infection (59.1%) and the overall amount of participants reporting either absolute or moderate inhibition reaching 77.8%.
A phase II trial using 20mL of a solution with 0.4-1.6% menthol which found dose-dependent relaxation up to 0.8% (reaching 47.4%), and these studies did not use oral ingestion of peppermint oil but rather used intragastric spraying techniques (spraying the solution directly on the antrum of the stomach with a spraying catheter.
Directly spraying low doses of menthol onto the stomach wall is able to potently suppress peristalsis of the stomach due to the muscle relaxing properties of menthol. This likely applies to oral supplementation as well
Peppermint is commonly thought to aid in dyspepsia, and is a component of an anti-dyspepsia combination formula known as STW-5 (alongside Lemon Balm, Licorice, caraway, bitter candy tuft, and matricaria flower) that appears effective although a combination of just peppermint oil (36mg thrice daily) with caraway oil (20mg thrice daily) also seems effective in relieving symptoms of dyspepsia such as pressure, sensation of fullness, and pain intensity secondary to relaxing effects on the stomach wall (acute doses of 90mg and 50mg, respectively). Benefits are seen in functional dyspepsia and non-ulcerous dyspepsia with infection of heliobacter pylori not influencing efficacy.
Peppermint oil appears to be somewhat effective in reducing symptoms of dyspepsia, although most of the research uses peppermint alongside caraway oil (at a 1.8:1 ratio). It seems to benefit dyspepsia in general, and the presence or absence of ulcerations of heliobacter pylori does not influence efficacy
In the intestines, peppermint has been noted to increase the DE50 and reduce maximum contractility of intestinal cells by acetylcholine and histamine, which was the most potent herb tested in this study against acetylcholine (Carum carvi, Matricaria chamonilla, and Melissa officinalis which was inactive) but underperformed relative to Citrus aurantium on histamine. 10mL pepperment oil (per liter solution) was as effective as 130µg atropine. These effects have been replicated elsewhere in other digestive tract tissue (including the trachea and sphincter of Oddi) and has also shown efficacy against carbachol-contracted ileal cells and serotonin induced contractions, and the observed relaxing effects are mostly due to the menthol content.
Peppermint oil (mostly menthol) appears to be able to relax muscle cells in the intestines as well as other muscle tissue in the gastrointestinal tract, and this relaxation appears to be relatively potent when compared against other herbs and quite general against various contracting stressors
When looking at the colon, one study (pepperment enemas) has noted a transient decrease in colonic motility associated with a 1mg/mL concentration of menthol causing reductions in colonic pressure.
One study in persons given colpermin capsules (0.2mL peppermint oil per capsule) four hours prior to a colonoscopy, the colonic spasms and pain associated with colonoscopy were significantly reduced and the treatment was deemed as more tolerable by both patient and practitioner.
Possibly general anti-diarrhetic and known relaxing effects in the colon, and in humans the relaxing effect of peppermint oil on the colon seems to occur within four hours of absorption
Peppermint oil has been noted to be somewhat beneficial as a first-line treatment (due to low cost and side-effects) in some patients with IBS based on results from a meta-analysis where a cumulative 392 patients given peppermint oil or placebo noted a relative risk of 0.43 (95% CI of 0.32-0.59), suggesting a halving of overall symptoms of IBS. These studies (one not located online) using a dosage in the range of 187-225mg two to four times daily (the ultimate dosage range being 450-750mg) and the reduced symptomology was mostly associated with abdominal pain and diarrhea. This was confirmed in a later study, where although abdominal pain and diarrhea were benefitted with peppermint oil other symptoms were unaffected.
Other studies not included in the aforementioned meta-analysis note that peppermint oil thrice daily over six weeks that is able to induce a reduction in symptoms (20%) yet is no longer effective two weeks after supplement cessation, and that Colpermin tablets given to outpatients with IBS was able to reduce abdominal pain and improve quality of life over 14 weeks. Colpermin tablets (3-6 capsules of 0.1mL; containing 187mg peppermint oil per capsule) appears to also be effective in children in the age range of 8-17.
Peppermint oil appears to be quite effective and reliable for reducing abdominal pain specifically in persons with irritable bowel syndrome, although this effect is only a band-aid effect and not curative
Peppermint oil appears to be traditionally recommended for the dissolution of gallstones and rat studies with oral ingestion of 100-1,000mg/kg peppermint oil have noted 30-140% increases in bile secretion which were later found to be dose and time dependent.
In a study using urosdeoxycholic acid (UDCA) at 11.1mg/kg in persons with gallstones and comparing it to an UDCA and menthol combination therapy (both at 4.75mg/kg) failed to note any differences in overall response rates but enhanced the frequency of complete dissolutions (up to 53% from 38%).
May possess chloretic activities and caused a reduction in gallstones
In southwestern Turkey, ingestion of peppermint or spearmint tea is said to cause a reduction in libido.
The addition of peppermint to rat drinking water at 20g/L (equal to making 250mL of tea from 5g of tea leaves) was able to reduce circulating testosterone by 23% although a more significant reduction was noted with spearmint (51%).
In women with hirsutism (21 overall, 12 diagnosed with PCOS), ingestion of spearmint tea at 5g tea leaves twice daily is associated with a significant reduction in free testosterone (29%) without altering total testosterone levels which has been confirmed in other trials. It is unsure if this applies to peppermint, as while peppermint is up to 50% menthol by weight spearmint is 29-74% carvone.
In rats, peppermint and spearmint both have antiandrogenic effects. Spearmint, but not peppermint, has been confirmed in human females to possess antiandrogenic effects
Supplementation of spearmint tea to women with hirsutism is able to increase circulating levels of estradiol (36%) with two 250mL cups of tea made from 5g tea leaves daily.
Peppermint has not been tested in regards to estrogen, but the related herb of spearmint has shown pro-estrogenic effects
Supplementation of spearmint tea to women with hirsutism is able to increase circulating levels of LH (26.8%) with two servings of spearmint tea (5g tea leaves each time) which has been noted in rats given 20g/L of peppermint in their drinking water, causing a 21% increase in luteinizing hormone.
Supplementation of spearmint tea to women with hirsutism does not significantly alter concentrations of sulfated DHEA.
A phenomena known as 'nipple crack' (a soreness of the nipples that may ultimately cause breaking of the skin, known to reduce the frequency of breastfeeding) may occur in breastfeeding mothers, and it appears that topical application of peppermint (either water or oil) is used in some mid-eastern countries for the treatment of sore nipples from breastfeeding.
When looking at trials, applying peppermint water (via cotton) to the areola followed breastfeeding (and washing the area prior to the next session) over the course of two weeks is able to reduce the frequency of nipple cracks from 23% in control to 7% while reducing the frequency of severe symptoms from 15% down to none. Benefits have also been seen with peppermint oil in a placebo-controlled trial, where topical application for six weeks exceeded both placebo and lanolin oil (reference) in the risk of developing nipple cracks.
Peppermint oil or water appears to be effective in reducing nipple cracks when applied topically
Cigarettes tend to sometimes contain menthol as a flavoring agent and to increase the 'cooling' sensation of inhalation (they are equally dangerous as cigarettes without menthol) and mentholated cigarettes seem to be able to inhibit metabolism of nicotine into its metabolite cotinine which is known to correlate with urinary menthol metabolites.
The process of nicotine conversion into cotinine is first catalyzed by the CYP2D6 enzyme (to form nicotine iminium ions) and then by aldehyde oxidase to form cotinine, and a peppermint drink (3 cups of 150mL peppermint tea) has been found to increase the nicotine to continine ratio in humans (from 0.995 to 1.327; a 33% increase).
Menthol has been confirmed to inhibit coumarin 7-hydroxylation (CYP2D6 mediated) with an IC50 of 70.49μM (the (-)-menthol isomer) or 37.77μM (the (+)-menthol isomer).
The addition of menthol (from peppermint) to cigarettes is common to enhance the 'cooling' sensation of inhaling a cigarette, and menthol appears to reduce the conversion of nicotine into continine via inhibiting the CYP2D6 enzyme
Ingestion of peppermint tea has been noted to inhibit the absorption of non-heme iron from a standardized meal by 84%, which was less than black tea (source of theaflavins at 79-94%) yet more than chocolate (cocoa extract) at 71%. The addition of milk did not alter absorption inhibition by peppermint tea.
May inhibit iron absorption when used as a tea
The LD50 of peppermint oil in rats is 4,400mg/kg, which is approximately 300mL/kg as an estimated human equivalent.
Toxicity has been established with peppermint oil, although it requires a significantly high oral dose. The recommended doses of peppermint oil seem to be free from toxicity
It appears that two particular components of peppermint oil, (+)-menthofuran and (-)-pulegone, may be somewhat toxic due to inducing brain lesions at high doses and their usage in aromatherapy not recommended. Although the former is usually low at all times, pulegone may be in concentration as high as 24.9% in leaves that are less than a week old being reduced to less than 1% after 45 days; the recommended pulegone content for peppermint oil is less than 2%.
It may be advisable to use older leaves which bioaccumulate menthol for supplemental and aromatherapy purposes
Contact dermatitis has been reported with peppermint oil and the leaves of peppermint.
One case study appears to have associated the usage of peppermint oil with interstitial nephritis and acute renal failure (mentioned in this review).
A few case studies suggest contact dermatitis with peppermint (common among plants and plausible) and one case study has noted kidney damage (no biological plausibility, requires investigation)
One case study has noted that ingestion of peppermint oil in a hospitalized patient with diarrhea (20 loose stools daily) resulted in a large burning sensation in the anus associated with peppermint oil, but that the patient was able to tolerate peppermint oil once defecation frequency was normalized with diet.
At least one case study has noted anal burning with peppermint oil when given to somebody with severe diarrhea, the patient seemed to tolerate peppermint oil when not suffering from said diarrhea
- Leuschner M, et al. Dissolution of gall stones with an ursodeoxycholic acid menthol preparation: a controlled prospective double blind trial. Gut. (1988)
- Varney E, Buckle J. Effect of inhaled essential oils on mental exhaustion and moderate burnout: a small pilot study. J Altern Complement Med. (2013)
- Hiki N, et al. Antiperistaltic effect and safety of L-menthol sprayed on the gastric mucosa for upper GI endoscopy: a phase III, multicenter, randomized, double-blind, placebo-controlled study. Gastrointest Endosc. (2011)
- Hiki N, et al. An open-label, single-arm study assessing the efficacy and safety of L: -menthol sprayed onto the gastric mucosa during upper gastrointestinal endoscopy. J Gastroenterol. (2011)
- Hiki N, et al. Multicenter phase II randomized study evaluating dose-response of antiperistaltic effect of L-menthol sprayed onto the gastric mucosa for upper gastrointestinal endoscopy. Dig Endosc. (2012)
- Hiki N, et al. A phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of L-menthol in upper gastrointestinal endoscopy. Clin Pharmacol Ther. (2011)
- May B, et al. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittelforschung. (1996)
- May B, Köhler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther. (2000)
- Holtmann G, et al. Effects of a fixed combination of peppermint oil and caraway oil on symptoms and quality of life in patients suffering from functional dyspepsia. Phytomedicine. (2003)
- Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res. (2000)
- Micklefield G, et al. Effects of intraduodenal application of peppermint oil (WS(R) 1340) and caraway oil (WS(R) 1520) on gastroduodenal motility in healthy volunteers. Phytother Res. (2003)
- WHO monographs on selected medicinal plants.
- Grigoleit HG, Grigoleit P. Pharmacology and preclinical pharmacokinetics of peppermint oil. Phytomedicine. (2005)
- Hawthorn M, et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. (1988)
- MECHANISM BY WHICH PEPPERMINT OIL EXERTS ITS RELAXANT EFFECT ON GASTROINTESTINAL SMOOTH MUSCLE.
- Regulation of Monoterpene Accumulation in Leaves of Peppermint.
- Biosynthesis of (−)-mintlactone and (+)-isomintlactone in Mentha piperita.
- Sugiura T, Uchida S, Namiki N. Taste-masking effect of physical and organoleptic methods on peppermint-scented orally disintegrating tablet of famotidine based on suspension spray-coating method. Chem Pharm Bull (Tokyo). (2012)
- Kline RM, et al. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. (2001)
- Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: a pharmacokinetic study.
- A pharmacokinetic comparison of two delayed-release peppermint oil preparations, Colpermin and Mintec, for treatment of the irritable bowel syndrome.
- Nolen HW 3rd, Friend DR. Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome. Pharm Res. (1994)
- Wang LH, Wang CC, Kuo SC. Vehicle and enhancer effects on human skin penetration of aminophylline from cream formulations: evaluation in vivo. J Cosmet Sci. (2007)
- Kligler B, Chaudhary S. Peppermint oil. Am Fam Physician. (2007)
- Göbel H, et al. Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type. Nervenarzt. (1996)
- Göbel H, Schmidt G, Soyka D. Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters. Cephalalgia. (1994)
- MacDougall JM, et al. Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues. Chem Res Toxicol. (2003)
- Ghazi AM, et al. Effect of mint drink on metabolism of nicotine as measured by nicotine to cotinine ratio in urine of Jordanian smoking volunteers. Nicotine Tob Res. (2011)
- Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. (2005)
- Dresser GK, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther. (2002)
- Kovar KA, et al. Blood levels of 1,8-cineole and locomotor activity of mice after inhalation and oral administration of rosemary oil. Planta Med. (1987)
- Moss M, et al. Modulation of cognitive performance and mood by aromas of peppermint and ylang-ylang. Int J Neurosci. (2008)
- Effects of Peppermint Scent Administration on Cognitive Video Game Performance.
- Heuberger E, Ilmberger J. The influence of essential oils on human vigilance. Nat Prod Commun. (2010)
- Lane B, et al. Examination of the effectiveness of peppermint aromatherapy on nausea in women post C-section. J Holist Nurs. (2012)
- Burns EE, et al. An investigation into the use of aromatherapy in intrapartum midwifery practice. J Altern Complement Med. (2000)
- Tate S. Peppermint oil: a treatment for postoperative nausea. J Adv Nurs. (1997)
- Anderson LA, Gross JB. Aromatherapy with peppermint, isopropyl alcohol, or placebo is equally effective in relieving postoperative nausea. J Perianesth Nurs. (2004)
- Schoenen J, Timsit-Berthier M. Contingent negative variation: methods and potential interest in headache. Cephalalgia. (1993)
- Beesley A, et al. Influence of peppermint oil on absorptive and secretory processes in rat small intestine. Gut. (1996)
- Schwartz RK. Olfaction and muscle activity: an EMG pilot study. Am J Occup Ther. (1979)
- Tutuian R, Castell DO. Review article: oesophageal spasm - diagnosis and management. Aliment Pharmacol Ther. (2006)
- Dalton CB, et al. Diffuse esophageal spasm. A rare motility disorder not characterized by high-amplitude contractions. Dig Dis Sci. (1991)
- Allen ML, DiMarino AJ Jr. Manometric diagnosis of diffuse esophageal spasm. Dig Dis Sci. (1996)
- Pimentel M, et al. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol. (2001)
- Mizuno S, et al. Oral peppermint oil is a useful antispasmodic for double-contrast barium meal examination. J Gastroenterol Hepatol. (2006)
- Imagawa A, et al. Peppermint oil solution is useful as an antispasmodic drug for esophagogastroduodenoscopy, especially for elderly patients. Dig Dis Sci. (2012)
- Vakil N, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. (2006)
- Patrick L. Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. Altern Med Rev. (2011)
- Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. (1991)
- Inamori M, et al. Early effects of peppermint oil on gastric emptying: a crossover study using a continuous real-time 13C breath test (BreathID system). J Gastroenterol. (2007)
- Iida H, et al. Early effects of oral administration of lafutidine with peppermint oil, compared with lafutidine alone, on intragastric pH values. Hepatogastroenterology. (2011)
- Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J. (1979)
- Rösch W, et al. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Phytomedicine. (2006)
- von Arnim U, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. (2007)
- Madisch A, et al. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. (2004)
- Fixed peppermint oil/caraway oil combination in functional dyspepsia – efficacy unaffected by H. pylori status.
- Forster HB, Niklas H, Lutz S. Antispasmodic effects of some medicinal plants. Planta Med. (1980)
- Reiter M, Brandt W. Relaxant effects on tracheal and ileal smooth muscles of the guinea pig. Arzneimittelforschung. (1985)
- Giachetti D, Taddei E, Taddei I. Pharmacological activity of essential oils on Oddi's sphincter. Planta Med. (1988)
- Evans BK, et al. Proceedings: Further studies on the correlation between biological activity and solubility of some carminatives. J Pharm Pharmacol. (1975)
- Shavakhi A, et al. Premedication with peppermint oil capsules in colonoscopy: a double blind placebo-controlled randomized trial study. Acta Gastroenterol Belg. (2012)
- Suares NC, Ford AC. Diagnosis and treatment of irritable bowel syndrome. Discov Med. (2011)
- Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
- Liu JH, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. (1997)
- Lech Y, et al. Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo. Ugeskr Laeger. (1988)
- Cappello G, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. (2007)
- Alam MS, et al. Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study. Mymensingh Med J. (2013)
- Merat S, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. (2010)
- Cholertic activity of Thapsia chem I, II, and III in rats: Comparison with terpenoid constituents and peppermint oil.
- Akdoğan M, et al. Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytother Res. (2007)
- Akdogan M, et al. Effects of peppermint teas on plasma testosterone, follicle-stimulating hormone, and luteinizing hormone levels and testicular tissue in rats. Urology. (2004)
- Grant P. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. (2010)
- ESSENTIAL OILS OF ANATOLIAN LABIATAE: A PROFILE.
- Huml S. Sore nipples. A new look at an old problem through the eyes of a dermatologist. Pract Midwife. (1999)
- Pugh LC, et al. A comparison of topical agents to relieve nipple pain and enhance breastfeeding. Birth. (1996)
- Sayyah Melli M, et al. Effect of peppermint water on prevention of nipple cracks in lactating primiparous women: a randomized controlled trial. Int Breastfeed J. (2007)
- Melli MS, et al. A randomized trial of peppermint gel, lanolin ointment, and placebo gel to prevent nipple crack in primiparous breastfeeding women. Med Sci Monit. (2007)
- Garten S, Falkner RV. Continual smoking of mentholated cigarettes may mask the early warning symptoms of respiratory disease. Prev Med. (2003)
- Giovino GA, et al. Epidemiology of menthol cigarette use. Nicotine Tob Res. (2004)
- Benowitz NL, Herrera B, Jacob P 3rd. Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther. (2004)
- Benowitz NL, et al. Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol Biomarkers Prev. (2010)
- Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr. (1999)
- Toxicities of peppermint and Pycnanthemum albescens oils.
- Thorup I, et al. Short term toxicity study in rats dosed with pulegone and menthol. Toxicol Lett. (1983)
- Herro E, Jacob SE. Mentha piperita (peppermint). Dermatitis. (2010)
- Anal burning and peppermint oil.